- In a 6-year, open-label study, overall discontinuation rates for adverse events were consistent with previous FLOMAX trials2 Learn more about this trial
- Incidence of drug-related adverse events decreased throughout the 6 years2
- In an observational survey of 20,000 patients, FLOMAX was as well tolerated in most patients with concomitant cardiovascular diseases and medication as in the overall population3 Learn more about this trial
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
1. Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
2. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003;170:498-502.
3. Coffey DS. Controversies in the management of lower urinary tract symptoms: an overview. Br J Urol. 1998;81(suppl 1):1-5.
